EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lentigo Maligna Treatment—An Update

Loredana Ungureanu iD, Alina Florentina Vasilovici, Ioana Irina Trufin, Adina Patricia Apostu, Salomea-Ruth Halmágyi iD

Journal of Clinical Medicine · 25.04.2024 · 13 (9) · 2527

DOI: 10.3390/jcm13092527 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.04.2024. Verfasst von Loredana Ungureanu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lentigo maligna (LM) is a melanoma in situ that is prevalent in chronically sun-damaged skin. Characterized by a slow growth pattern and high mutation rates due to chronic UV exposure, LM poses diagnostic and therapeutic challenges, particularly given its tendency to mimic other skin lesions and its occurrence in cosmetically sensitive areas. Its diagnosis is based on an integrated approach using dermoscopy and reflectance confocal microscopy (RCM). Despite its slow progression, LM can evolve into lentigo maligna melanoma (LMM), making its treatment necessary. Treatment modalities encompass both surgical and non-surgical methods. Surgical treatments like Wide Local Excision (WLE) and Mohs Micrographic Surgery (MMS) aim for clear histological margins. WLE, a standard melanoma surgery, faces challenges from LM’s subclinical extensions, which increase the recurrence risk. MMS, effective for large or poorly defined lesions, is defined by precise margin control while considering cosmetic outcomes. Non-surgical options, including radiotherapy and imiquimod, are alternatives for non-surgical candidates. Radiotherapy has been effective since the 1950s, offering good control and cosmetic results, especially for older patients. Imiquimod, an immunomodulator, shows promise in treating LM, though its application remains off-label. The increasing incidence of LM/LMM necessitates a balance in treatment choices to minimize recurrence and maintain cosmetic integrity. A multidisciplinary approach, integrating clinical examination with dermoscopy and RCM and histological assessment, is essential for accurate diagnosis and effective LM management.

Schlagwörter

Stichwörter der Autor:innen

imiquimodlentigo malignaradiotherapysurgerytreatment

Autor:innen und Institutionen

  • Department of Dermatology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.
  • Department of Dermatology, Emergency County Hospital, 400006 Cluj-Napoca, Romania.
  • Clinical Hospital of Infectious Diseases, 400000 Cluj-Napoca, Romania.

ORCID-Profile: Loredana Ungureanu, Salomea-Ruth Halmágyi

Zitieren

APA

Ungureanu, L., Vasilovici, A. F., Trufin, I. I., Apostu, A. P., & Halmágyi, S. R. (2024). Lentigo Maligna Treatment—An Update. Journal of Clinical Medicine, 13(9), 2527. https://doi.org/10.3390/jcm13092527

Vancouver

Ungureanu L, Vasilovici AF, Trufin II, Apostu AP, Halmágyi SR. Lentigo Maligna Treatment—An Update. Journal of Clinical Medicine. 2024;13(9):2527. doi:10.3390/jcm13092527

BibTeX
@article{Ungureanu2024,
  author = {Ungureanu, Loredana and Vasilovici, Alina Florentina and Trufin, Ioana Irina and Apostu, Adina Patricia and Halmágyi, Salomea-Ruth},
  title = {Lentigo Maligna Treatment—An Update},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {9},
  pages = {2527},
  doi = {10.3390/jcm13092527}
}
Kostenlos starten →